These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 8804876)

  • 1. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission.
    Papatheodoridis GV; Katsoulidou A; Touloumi G; Delladetsima JK; Hatzakis A; Tassopoulos NC
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients.
    Manesis EK; Papaioannou C; Gioustozi A; Kafiri G; Koskinas J; Hadziyannis SJ
    Hepatology; 1997 Sep; 26(3):734-9. PubMed ID: 9303505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha interferon treatment in chronic hepatitis C.
    Idéo G; Bellobuono A; Mondazzi L; Tempini S; Bellati G; Idéo GM; Silini E
    Clin Exp Rheumatol; 1995; 13 Suppl 13():S167-73. PubMed ID: 8730501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
    Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa.
    Zeuzem S; Lee JH; Franke A; Rüster B; Prümmer O; Herrmann G; Roth WK
    Hepatology; 1998 Apr; 27(4):1149-56. PubMed ID: 9537457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B.
    Sim H; Yim C; Krajden M; Heathcote J
    Am J Gastroenterol; 1998 Jan; 93(1):39-43. PubMed ID: 9448171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of interferon-alpha induction therapy on genotype 2b/3a and low viral load hepatitis C virus infection. A randomized multicentre study.
    Bjøro K; Bell H; Myrvang B; Skaug K; Raknerud N; Sandvei P; Størseth S; Ritland S; Lund-Tønnesen S; Bucher A; Hellum KB
    Scand J Gastroenterol; 2002 Mar; 37(3):344-9. PubMed ID: 11916198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of an initial daily dosing regimen of interferon-alpha-2a in treatment-naive patients with chronic hepatitis C and HCV genotype 1.
    Desch S; Vaeth T; Tamba M; Klinker H; Langmann P
    Eur J Med Res; 2001 Jun; 6(6):242-6. PubMed ID: 11432797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C.
    Pawlotsky JM; Darthuy F; Rémiré J; Pellet C; Udin L; Stuyver L; Roudot-Thoraval F; Duvoux C; Douvin C; Mallat A
    J Med Virol; 1995 Nov; 47(3):285-91. PubMed ID: 8551282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [HCV RNA clearance after treatment with interferon-alpha in chronic hemodialysis patients with or without coinfection by HGV/HGBV-C].
    Rostaing L; Izopet J; Moussion F; Alric L; Verdier D; That HT; Duffaut M; Durand D; Puel J; Suc JM
    Nephrologie; 1997; 18(7):281-6. PubMed ID: 9496568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment.
    Bellobuono A; Mondazzi L; Tempini S; Silini E; Idéo G
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1169-77. PubMed ID: 9471022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changes in quantitative HCV RNA titers during interferon alpha 2B therapy in patients with chronic hepatitis C infection.
    Tong MJ; Blatt LM; Conrad A; Hur Y; Russell J; El-Farra NS; Co RL
    Am J Gastroenterol; 1998 Apr; 93(4):601-5. PubMed ID: 9576455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-alpha in chronic hepatitis C. TriVeneto Viral Hepatitis Group.
    Chemello L; Cavalletto L; Casarin C; Bonetti P; Bernardinello E; Pontisso P; Donada C; Belussi F; Martinelli S; Alberti A
    Ann Intern Med; 1996 Jun; 124(12):1058-60. PubMed ID: 8633819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.
    Ampurdanés S; Olmedo E; Maluenda MD; Forns X; López-Labrador FX; Costa J; Sánchez-Tapias JM; de Anta MT; Rodés J
    J Hepatol; 1996 Dec; 25(6):827-32. PubMed ID: 9007709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.
    Martinot-Peignoux M; Marcellin P; Pouteau M; Castelnau C; Boyer N; Poliquin M; Degott C; Descombes I; Le Breton V; Milotova V
    Hepatology; 1995 Oct; 22(4 Pt 1):1050-6. PubMed ID: 7557850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.